報價延遲最少15分鐘:2025/01/11 17:12 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6644 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.46/0.81
|
|
企業價值
77.78M
|
| 資產負債 |
|
每股賬面淨值
0.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
675.00K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:12 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. |